<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00534274</url>
  </required_header>
  <id_info>
    <org_study_id>FLT01 - UC-0140/0505</org_study_id>
    <secondary_id>FRE-FNCLCC-FLT-01/0505</secondary_id>
    <secondary_id>EU-20754</secondary_id>
    <secondary_id>2005-005166-37</secondary_id>
    <nct_id>NCT00534274</nct_id>
  </id_info>
  <brief_title>Positron Emission Tomography Using 3'-Deoxy-3'-(18F) Fluorothymidine in Treating Women With Locally Advanced Cancer in One Breast Who Are Receiving Chemotherapy</brief_title>
  <official_title>Study of Positron Emission Tomography With 3'-Deoxy-3'-[18F] Fluoro-thymidine ([18F]-FLT) for the Evaluation of Response to Neoadjuvant Chemotherapy for Cancers of the Breast</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Diagnostic procedures, such as positron emission tomography (PET) using
      3'-deoxy-3'-(18F) fluorothymidine, may be effective in assessing the response to chemotherapy
      before surgery in treating locally advanced breast cancer.

      PURPOSE: This clinical trial is studying how well positron emission tomography using
      3'-deoxy-3'-(18F) fluorothymidine works in treating women with locally advanced cancer in one
      breast who are receiving chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Evaluate the efficacy of positron emission tomography (PET) utilizing 3'-deoxy-3'-(18F)
           fluorothymidine (^18F-FLT) to correctly identify response to neoadjuvant chemotherapy in
           women with locally advanced unilateral breast cancer.

        -  Correlate PET-^18F-FLT results with histological response.

      Secondary

        -  Evaluate the correlation of early changes in tumor uptake of ^18F-FLT after the first
           course of chemotherapy with complete response after treatment completion.

        -  Evaluate the correlation of early changes in tumor uptake of ^18F-FLT with histologic
           response in biopsies obtained after 1 course of chemotherapy.

        -  Determine if the initial intensity of tumor uptake is a predictive value of response to
           chemotherapy.

        -  Determine if initial intensity of tumor uptake of ^18F-FLT varies according to
           histologic type of tumor, indices of proliferation, and tumor cellularity before
           therapy.

        -  Determine if the tumor uptake of ^18F-FLT during therapy varies according to histologic
           type of tumor, indices of proliferation, and tumor cellularity before therapy.

        -  Evaluate the role of TK1 on the kinetics of ^18 F-FLT.

        -  Analyze serum.

        -  Research biomarkers of genomics, transcription, and proteomics.

        -  Evaluate the toxicity of ^18F-FLT.

      OUTLINE: This is a multicenter study.

      Patients receive 3'-deoxy-3'-(18F) fluorothymidine (^18F-FLT) IV and undergo positron
      emission tomography (PET) before the first and second courses of neoadjuvant chemotherapy.
      Patients receiving bisequential chemotherapy undergo ^18F-FLT-PET before the change in drugs
      (usually the fourth or fifth course). All patients undergo a final ^18F-FLT-PET after the
      last chemotherapy course but before surgery.

      After completion of study therapy, patients are followed for 1 month.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intensity of tumor uptake of 3'-deoxy-3'-(18F) fluorothymidine (18F-FLT) determined visually and correlated with histological or surgical response according to Sataloff criteria</measure>
    <time_frame>Post surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intensity of tumor uptake of 18F-FLT by standardized uptake value (SUV)</measure>
    <time_frame>Post surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of tumoral uptake as seen by positron emission tomography (PET) before, during, and after therapy as determined visually and by SUV</measure>
    <time_frame>Post surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of the tumoral uptake of 18F-FLT on initial exam visually and by SUV</measure>
    <time_frame>post surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histologic parameters: type, grade, mitotic index, CCIS , and microbiopsy embols after first course of chemotherapy (and on microbiopsy before therapeutic change of sequence in patients receiving bisequential chemotherapy)</measure>
    <time_frame>post surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunohistochemical evaluation (estrogen and progesterone receptors, c-erbB2, Ki-67, e-cadherin)</measure>
    <time_frame>Post-surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of thymidine kinase 1 (TK1)</measure>
    <time_frame>Post surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity by CTC-AE v. 3.0</measure>
    <time_frame>Post surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>TEP FLT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>3'-deoxy-3'-[18F]fluorothymidine</intervention_name>
    <arm_group_label>TEP FLT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

        Inclusion criteria:

          -  Histologically confirmed unilateral breast cancer

               -  T2 or T3, any N, M0

               -  Unifocal by mammography and ultrasound

          -  Negative for c-erbB2 by immunohistochemistry (IHC)

          -  Planning neoadjuvant chemotherapy comprising anthracyclines and/or taxanes, alone or
             combined

          -  Measurable disease by ultrasound

          -  Hormone receptor status not specified

        Exclusion criteria:

          -  Bilateral disease

          -  Multifocal tumor

          -  Invasive grade I lobular cancer

          -  Metastatic disease

          -  Stage â‰¥ T4 disease

          -  Cutaneous invasion, major adherence, or inflammatory disease

          -  Tumor overexpressing c-erbB2 by IHC (HER 2+++)

          -  Suspected clinical or radiological lesion (examined or not)

        PATIENT CHARACTERISTICS:

        Inclusion criteria:

          -  ECOG performance status 0-1

          -  Female

          -  Menopausal status not specified

          -  Hematologic, hepatic, and renal function normal

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

        Exclusion criteria:

          -  Alcohol dependency or prior reaction to ethanol injection

          -  Impossible to receive study therapy due to geographical, social, or psychological
             reasons

          -  Prisoners or patients under supervision

        PRIOR CONCURRENT THERAPY:

        Inclusion criteria:

          -  See Disease Characteristics

        Exclusion criteria:

          -  Participation in another concurrent therapeutic study with an experimental drug
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Couturier, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Hospitalier Regional et Universitaire d'Angers</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Regional et Universitaire d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49036</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de la Cote Basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Andre</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux - Hopital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Bordeaux Nord Aquitaine</name>
      <address>
        <city>Bordeaux</city>
        <zip>33300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hopital A. Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Lutte Contre le Cancer Georges-Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional Rene Gauducheau</name>
      <address>
        <city>Nantes-Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de l'Archet CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>F-06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Rene Huguenin</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92211</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Bretonneau de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2007</study_first_submitted>
  <study_first_submitted_qc>September 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2007</study_first_posted>
  <last_update_submitted>December 14, 2014</last_update_submitted>
  <last_update_submitted_qc>December 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dideoxynucleosides</mesh_term>
    <mesh_term>Alovudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

